Find Clinical Trials

All CategoriesMedical Conditions»Immune Disorders»AIDS»Australia



Join Paid Clinical Trials



  • Condition:   HIV-1 Infection
    Intervention:  
    Sponsor:   Kirby Institute
    Recruiting

  • Conditions:   HIV;   HIV-associated Neurocognitive Disorder (HAND)
    Intervention:  
    Sponsor:   St Vincent's Hospital, Sydney
    Recruiting

  • Condition:   HIV
    Intervention:   Drug: 3BNC117-Copper-64
    Sponsors:   Bayside Health;   The Peter Doherty Institute for Infection and Immunity;   Monash University;   Monash Health;   Rockefeller University;   Austin Health
    Recruiting

  • Condition:   Chronic Lung Allograft Dysfunction (CLAD)
    Interventions:   Drug: Bone-marrow derived MSCs;   Drug: Placebo
    Sponsors:   The University of Queensland;   Isopogen;   Cell and Tissue Therapies
    Recruiting

  • Condition:   HIV Infections
    Interventions:   Drug: DTG + 3TC;   Drug: TAF based regimen (TBR)
    Sponsors:   ViiV Healthcare;   GlaxoSmithKline
    Recruiting

  • Condition:   Hepatitis C
    Interventions:   Drug: SOF/VEL for 6 weeks;   Drug: SOF/VEL for 12 weeks
    Sponsor:   Kirby Institute
    Recruiting

  • Condition:   HIV-1-infection
    Interventions:   Drug: Saline;   Drug: Lefitolimod;   Drug: 3BNC117 and 10-1074
    Sponsors:   University of Aarhus;   Aalborg Universitetshospital;   Odense University Hospital;   Rigshospitalet, Denmark;   Hvidovre University Hospital;   The Peter Doherty Institute for Infection and Immunity;   University of Utah
    Not yet recruiting

  • Condition:   High Risk Localised Pancreatic Cancer
    Intervention:   Radiation: Stereotactic Body Radiotherapy (SBRT)
    Sponsor:   Royal North Shore Hospital
    Recruiting

  • Condition:   Hepatitis C, Acute
    Interventions:   Drug: Paritaprevir/ritonavir/ombitasvir;   Drug: Dasabuvir;   Drug: Ribavirin;   Drug: Glecaprevir/pibrentasvir
    Sponsors:   Kirby Institute;   AbbVie
    Recruiting

  • Conditions:   Otitis Media;   Conductive Hearing Loss
    Intervention:   Behavioral: facilitator
    Sponsors:   Menzies School of Health Research;   The Balnaves Foundation;   The Northern Territory Government;   The Australian Government Department of Health
    Not yet recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Anal Carcinoma;   HIV Infection;   Kaposi Sarcoma;   Lung Carcinoma;   Metastatic Malignant Solid Neoplasm;   Recurrent Classic Hodgkin Lymphoma;   Refractory Classic Hodgkin Lymphoma;   Unresectable Solid Neoplasm
    Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Neurocognitive Function;   Mood
    Interventions:   Dietary Supplement: Swisse Ultiboost Memory + Focus;   Other: Placebo
    Sponsors:   Swisse Wellness Pty Ltd;   Swinburne University of Technology
    Recruiting

  • Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
    Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab;   Drug: Cobimetinib
    Sponsor:   Peter MacCallum Cancer Centre, Australia
    Recruiting

  • Conditions:   Acquired Immune Deficiency Syndrome (AIDS);   HIV Infections
    Interventions:   Drug: E/C/F/TAF;   Drug: E/C/F/TAF (Low Dose)
    Sponsor:   Gilead Sciences
    Recruiting

  • Condition:   Nonsmall Cell Lung Cancer
    Intervention:   Drug: AZD4205
    Sponsor:   Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Recruiting

  • Condition:   HIV Infections
    Interventions:   Drug: NRTIs;   Drug: Dolutegravir;   Drug: Darunavir;   Drug: Ritonavir
    Sponsors:   Kirby Institute;   UNITAID;   National Institute of Allergy and Infectious Diseases (NIAID);   National Health and Medical Research Council, Australia;   ViiV Healthcare;   Janssen Pharmaceutica
    Recruiting

  • Condition:   Breast Cancer
    Interventions:   Device: Breathe Well;   Device: RPM
    Sponsor:   University of Sydney
    Recruiting

  • Condition:   Metastatic Melanoma
    Interventions:   Radiation: Palliative radiotherapy;   Drug: Dabrafenib and trametinib (combination)
    Sponsors:   Australia and New Zealand Melanoma Trials Group;   Melanoma Institute Australia
    Recruiting

  • Conditions:   Melanoma;   Brain Metastases
    Interventions:   Procedure: Craniotomy scheduled;   Procedure: Collection for non-craniotomy
    Sponsors:   University of Pittsburgh;   GlaxoSmithKline
    Recruiting

  • Conditions:   Rare Disorders;   Undiagnosed Disorders;   Disorders of Unknown Prevalence;   Cornelia De Lange Syndrome;   Prenatal Benign Hypophosphatasia;   Perinatal Lethal Hypophosphatasia;   Odontohypophosphatasia;   Adult Hypophosphatasia;   Childhood-onset Hypophosphatasia;   Infantile Hypophosphatasia;   Hypophosphatasia;   Kabuki Syndrome;   Bohring-Opitz Syndrome;   Narcolepsy Without Cataplexy;   Narcolepsy-cataplexy;   Hypersomnolence Disorder;   Idiopathic Hypersomnia Without Long Sleep Time;   Idiopathic Hypersomnia With Long Sleep Time;   Idiopathic Hypersomnia;   Kleine-Levin Syndrome;   Kawasaki Disease;   Leiomyosarcoma;   Leiomyosarcoma of the Corpus Uteri;   Leiomyosarcoma of the Cervix Uteri;   Leiomyosarcoma of Small Intestine;   Acquired Myasthenia Gravis;   Addison Disease;   Hyperacusis (Hyperacousis);   Juvenile Myasthenia Gravis;   Transient Neonatal Myasthenia Gravis;   Williams Syndrome;   Lyme Disease;   Myasthenia Gravis;   Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome);   Isolated Klippel-Feil Syndrome;   Frasier Syndrome;   Denys-Drash Syndrome;   Beckwith-Wiedemann Syndrome;   Emanuel Syndrome;   Isolated Aniridia;   Beckwith-Wiedemann Syndrome Due to Paternal Uniparental Disomy of Chromosome 11;   Beckwith-Wiedemann Syndrome Due to Imprinting Defect of 11p15;   Beckwith-Wiedemann Syndrome Due to 11p15 Translocation/Inversion;   Beckwith-Wiedemann Syndrome Due to 11p15 Microduplication;   Beckwith-Wiedemann Syndrome Due to 11p15 Microdeletion;   Axenfeld-Rieger Syndrome;   Aniridia-intellectual Disability Syndrome;   Aniridia - Renal Agenesis - Psychomotor Retardation;   Aniridia - Ptosis - Intellectual Disability - Familial Obesity;   Aniridia - Cerebellar Ataxia - Intellectual Disability;   Aniridia - Absent Patella;   Aniridia;   Peters Anomaly - Cataract;   Peters Anomaly;   Potocki-Shaffer Syndrome;   Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11;   Silver-Russell Syndrome Due to Imprinting Defect of 11p15;   Silver-Russell Syndrome Due to 11p15 Microduplication;   Syndromic Aniridia;   WAGR Syndrome;   Wolf-Hirschhorn Syndrome;   4p16.3 Microduplication Syndrome;   4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome;   Autosomal Recessive Stickler Syndrome;   Stickler Syndrome Type 2;   Stickler Syndrome Type 1;   Stickler Syndrome;   Mucolipidosis Type 4;   X-linked Spinocerebellar Ataxia Type 4;   X-linked Spinocerebellar Ataxia Type 3;   X-linked Intellectual Disability - Ataxia - Apraxia;   X-linked Progressive Cerebellar Ataxia;   X-linked Non Progressive Cerebellar Ataxia;   X-linked Cerebellar Ataxia;   Vitamin B12 Deficiency Ataxia;   Toxic Exposure Ataxia;   Unclassified Autosomal Dominant Spinocerebellar Ataxia;   Thyroid Antibody Ataxia;   Sporadic Adult-onset Ataxia of Unknown Etiology;   Spinocerebellar Ataxia With Oculomotor Anomaly;   Spinocerebellar Ataxia With Epilepsy;   Spinocerebellar Ataxia With Axonal Neuropathy Type 2;   Spinocerebellar Ataxia Type 8;   Spinocerebellar Ataxia Type 7;   Spinocerebellar Ataxia Type 6;   Spinocerebellar Ataxia Type 5;   Spinocerebellar Ataxia Type 4;   Spinocerebellar Ataxia Type 37;   Spinocerebellar Ataxia Type 36;   Spinocerebellar Ataxia Type 35;   Spinocerebellar Ataxia Type 34;   Spinocerebellar Ataxia Type 32;   Spinocerebellar Ataxia Type 31;   Spinocerebellar Ataxia Type 30;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 29;   Spinocerebellar Ataxia Type 28;   Spinocerebellar Ataxia Type 27;   Spinocerebellar Ataxia Type 26;   Spinocerebellar Ataxia Type 25;   Spinocerebellar Ataxia Type 23;   Spinocerebellar Ataxia Type 22;   Spinocerebellar Ataxia Type 21;   Spinocerebellar Ataxia Type 20;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 19/22;   Spinocerebellar Ataxia Type 18;   Spinocerebellar Ataxia Type 17;   Spinocerebellar Ataxia Type 16;   Spinocerebellar Ataxia Type 15/16;   Spinocerebellar Ataxia Type 14;   Spinocerebellar Ataxia Type 13;   Spinocerebellar Ataxia Type 12;   Spinocerebellar Ataxia Type 11;   Spinocerebellar Ataxia Type 10;   Spinocerebellar Ataxia Type 1 With Axonal Neuropathy;   Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia - Unknown;   Spinocerebellar Ataxia - Dysmorphism;   Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Spectrin-associated Autosomal Recessive Cerebellar Ataxia;   Spasticity-ataxia-gait Anomalies Syndrome;   Spastic Ataxia With Congenital Miosis;   Spastic Ataxia - Corneal Dystrophy;   Spastic Ataxia;   Rare Hereditary Ataxia;   Rare Ataxia;   Recessive Mitochondrial Ataxia Syndrome;   Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Posterior Column Ataxia - Retinitis Pigmentosa;   Post-Stroke Ataxia;   Post-Head Injury Ataxia;   Post Vaccination Ataxia;   Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract;   Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus;   Non-progressive Cerebellar Ataxia With Intellectual Disability;   Non-hereditary Degenerative Ataxia;   Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity;   Olivopontocerebellar Atrophy - Deafness;   NARP Syndrome;   Myoclonus - Cerebellar Ataxia - Deafness;   Multiple System Atrophy, Parkinsonian Type;   Multiple System Atrophy, Cerebellar Type;   Multiple System Atrophy;   Maternally-inherited Leigh Syndrome;   Machado-Joseph Disease Type 3;   Machado-Joseph Disease Type 2;   Machado-Joseph Disease Type 1;   Lethal Ataxia With Deafness and Optic Atrophy;   Leigh Syndrome;   Leukoencephalopathy With Mild Cerebellar Ataxia and White Matter Edema;   Leukoencephalopathy - Ataxia - Hypodontia - Hypomyelination;   Leigh Syndrome With Nephrotic Syndrome;   Leigh Syndrome With Leukodystrophy;   Leigh Syndrome With Cardiomyopathy;   Late-onset Ataxia With Dementia;   Intellectual Disability-hyperkinetic Movement-truncal Ataxia Syndrome;   Infection or Post Infection Ataxia;   Infantile-onset Autosomal Recessive Nonprogressive Cerebellar Ataxia;   Infantile Onset Spinocerebellar Ataxia;   GAD Ataxia;   Hereditary Episodic Ataxia;   Gliadin/Gluten Ataxia;   Friedreich Ataxia;   Fragile X-associated Tremor/Ataxia Syndrome;   Familial Paroxysmal Ataxia;   Exposure to Medications Ataxia;   Episodic Ataxia With Slurred Speech;   Episodic Ataxia Unknown Type;   Episodic Ataxia Type 7;   Episodic Ataxia Type 6;   Episodic Ataxia Type 5;   Episodic Ataxia Type 4;   Episodic Ataxia Type 3;   Episodic Ataxia Type 1;   Epilepsy and/or Ataxia With Myoclonus as Major Feature;   Early-onset Spastic Ataxia-neuropathy Syndrome;   Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity;   Early-onset Cerebellar Ataxia With Retained Tendon Reflexes;   Early-onset Ataxia With Dementia;   Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia;   Dilated Cardiomyopathy With Ataxia;   Cataract - Ataxia - Deafness;   Cerebellar Ataxia, Cayman Type;   Cerebellar Ataxia With Peripheral Neuropathy;   Cerebellar Ataxia - Hypogonadism;   Cerebellar Ataxia - Ectodermal Dysplasia;   Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss;   Brain Tumor Ataxia;   Brachydactyly - Nystagmus - Cerebellar Ataxia;   Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia;   Autosomal Recessive Syndromic Cerebellar Ataxia;   Autosomal Recessive Spastic Ataxia With Leukoencephalopathy;   Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay;   Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria;   Autosomal Recessive Spastic Ataxia;   Autosomal Recessive Metabolic Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine;   Autosomal Recessive Ataxia, Beauce Type;   Autosomal Recessive Ataxia Due to Ubiquinone Deficiency;   Autosomal Recessive Ataxia Due to PEX10 Deficiency;   Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia;   Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia;   Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome;   Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity;   Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency;   Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect;   Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion;   Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation;   Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness;   Autosomal Recessive Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly;   Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation;   Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy;   Autosomal Dominant Spastic Ataxia Type 1;   Autosomal Dominant Spastic Ataxia;   Autosomal Dominant Optic Atrophy;   Ataxia-telangiectasia Variant;   Ataxia-telangiectasia;   Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy;   Autosomal Dominant Cerebellar Ataxia Type 4;   Autosomal Dominant Cerebellar Ataxia Type 3;   Autosomal Dominant Cerebellar Ataxia Type 2;   Autosomal Dominant Cerebellar Ataxia Type 1;   Autosomal Dominant Cerebellar Ataxia;   Ataxia-telangiectasia-like Disorder;   Ataxia-intellectual Disability-oculomotor Apraxia-cerebellar Cysts Syndrome;   Ataxia-deafness-intellectual Disability Syndrome;   Ataxia With Vitamin E Deficiency;   Ataxia With Dementia;   Ataxia Neuropathy Spectrum;   Ataxia - Tapetoretinal Degeneration;   Ataxia - Photosensitivity - Short Stature;   Ataxia - Pancytopenia;   Ataxia - Oculomotor Apraxia Type 1;   Ataxia - Hypogonadism - Choroidal Dystrophy;   Ataxia - Other;   Ataxia - Genetic Diagnosis - Unknown;   Acquired Ataxia;   Adult-onset Autosomal Recessive Cerebellar Ataxia;   Alcohol Related Ataxia;   Multiple Endocrine Neoplasia;   Multiple Endocrine Neoplasia Type II;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Multiple Endocrine Neoplasia, Type IV;   Multiple Endocrine Neoplasia, Type 3;   Multiple Endocrine Neoplasia (MEN) Syndrome;   Multiple Endocrine Neoplasia Type 2B;   Multiple Endocrine Neoplasia Type 2A;   Atypical Hemolytic Uremic Syndrome;   Atypical HUS;   Wiedemann-Steiner Syndrome;   Breast Implant-Associated Anaplastic Large Cell Lymphoma;   Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA);   Hemophagocytic Lymphohistiocytosis;   Behcet's Disease;   Alagille Syndrome;   Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD);   Lowe Syndrome;   Pitt Hopkins Syndrome;   1p36 Deletion Syndrome;   Jansen Type Metaphyseal Chondrodysplasia;   Cockayne Syndrome;   Chronic Recurrent Multifocal Osteomyelitis;   CRMO;   Malan Syndrome;   Hereditary Sensory and Autonomic Neuropathy Type Ie
    Intervention:  
    Sponsors:   Sanford Health;   National Ataxia Foundation;   International WAGR Syndrome Association;   4p- Support Group;   ML4 Foundation;   Cornelia de Lange Syndrome Foundation;   Stickler Involved People;   Kawasaki Disease Foundation;   Klippel-Feil Syndrome Alliance;   Klippel-Feil Syndrome Freedom;   Hyperacusis Research Limited;   Hypersomnia Foundation;   Kabuki Syndrome Network;   Kleine-Levin Syndrome Foundation;   Leiomyosarcoma Direct Research Foundation;   Marinesco-Sjogren Syndrome Support Group;   Mucolipidosis Type IV (ML4) Foundation;   People with Narcolepsy 4 People with Narcolepsy (PWN4PWN);   Soft Bones Incorporated;   American Multiple Endocrine Neoplasia Support;   Atypical Hemolytic Uremic Syndrome Foundation;   All Things Kabuki;   Wiedemann-Steiner Syndrome Foundation;   Breast Implant Victim Advocates;   PROS Foundation;   American Behcet's Disease Association
    Recruiting

  • Condition:   Cognitive Dysfunction
    Intervention:   Device: Dual-monitoring
    Sponsors:   Brisbane Hand and Upper Limb Research Institute;   Medtronic;   CAS Medical Systems, Inc.
    Recruiting

  • Condition:   Prostate Cancer
    Interventions:   Drug: Zoledronic acid;   Drug: Placebo
    Sponsor:   Austin Health
    Recruiting

  • Condition:   Female Reproductive Problem
    Intervention:   Procedure: Total Laparoscopic Hysterectomy
    Sponsor:   Queensland Centre for Gynaecological Cancer
    Recruiting

  • Conditions:   Mild Cognitive Impairment;   Alzheimer Disease;   Alzheimer Dementia;   Dementia, Vascular;   Dementia With Lewy Bodies;   Cognitive Impairment;   Tauopathies;   Neurodegenerative Diseases;   Neurocognitive Disorders;   Cognitive Disorder
    Interventions:   Drug: N-831(Traneurocin) 10 mg QD;   Drug: NA-831 (Traneurocin) 20 mg QD;   Drug: NA-831 (Traneurocin) 40 mg QD;   Drug: Placebo oral capsule QD
    Sponsors:   NeuroActiva, Inc.;   The Florey Institute of Neuroscience and Mental Health
    Not yet recruiting

  • Condition:   Healthy Ageing
    Interventions:   Other: Treatment cookies;   Other: Control cookies
    Sponsors:   University of Manitoba;   University of Southern Queensland;   Advance Queensland;   Nutrafruit Pty Ltd;   Nature Pacific Pty Ltd
    Recruiting

  • Condition:   Osteoarthritis, Knee
    Interventions:   Dietary Supplement: Swisse High Strength Deep Sea Krill Oil;   Other: Placebo
    Sponsors:   Swisse Wellness Pty Ltd;   Commonwealth Scientific and Industrial Research Organisation, Australia
    Recruiting

  • Conditions:   Gaucher Disease;   Cerebroside Lipidosis Syndrome;   Glucocerebrosidase Deficiency Disease;   Glucosylceramide Beta-Glucosidase Deficiency Disease
    Intervention:  
    Sponsor:   Genzyme, a Sanofi Company
    Recruiting

  • Conditions:   Wounds and Injuries;   Acute Coagulopathy
    Interventions:   Drug: Tranexamic Acid;   Drug: Placebo
    Sponsors:   Monash University;   National Health and Medical Research Council, Australia;   Health Research Council, New Zealand
    Recruiting

  • Condition:   Major Depressive Disorder
    Intervention:   Drug: Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.
    Sponsors:   Baker IDI Heart and Diabetes Institute;   The Alfred;   Monash Medical Centre;   Ballarat Health Services
    Recruiting

  • Condition:   Education, Medical
    Interventions:   Other: PlayMed;   Other: Online Package;   Other: Paper Guidelines
    Sponsor:   The University of New South Wales
    Recruiting

  • Conditions:   Retinopathy of Prematurity;   Pain;   Acupuncture;   Premature Infant
    Interventions:   Device: Magnetic acupuncture;   Device: stickers (magnets removed)
    Sponsor:   University of Alberta
    Recruiting

  • Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4 Neuroblastoma
    Interventions:   Drug: Carboplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Lymphedema;   Breast Neoplasm
    Intervention:  
    Sponsors:   Universitaire Ziekenhuizen Leuven;   University of Sydney
    Recruiting

  • Conditions:   Deafness; Sensoneural Single Sided;   Conductive Hearing Loss;   Mixed Hearing Loss
    Intervention:   Device: Investigational device - Sound Processor
    Sponsor:   Cochlear Bone Anchored Solutions
    Recruiting

  • Conditions:   Cancer Survivor;   Hodgkin Lymphoma;   Leukemia in Remission;   Lymphoid Leukemia in Remission;   Osteosarcoma
    Interventions:   Other: Assessment of Therapy Complications;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Central Nervous System Neoplasm;   Childhood Immature Teratoma;   Childhood Langerhans Cell Histiocytosis;   Childhood Malignant Neoplasm;   Childhood Mature Teratoma;   Congenital Mesoblastic Nephroma;   Desmoid-Type Fibromatosis;   Lymphoproliferative Disorder;   Myeloproliferative Neoplasm;   Stromal Neoplasm
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Medical Chart Review
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia (AML);   Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
    Interventions:   Drug: gilteritinib;   Drug: azacitidine
    Sponsor:   Astellas Pharma Global Development, Inc.
    Recruiting

  • Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Clear Cell Sarcoma of the Kidney;   Congenital Mesoblastic Nephroma;   Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Rhabdoid Tumor of the Kidney;   Stage I Kidney Wilms Tumor;   Stage I Renal Cell Cancer AJCC v6 and v7;   Stage II Kidney Wilms Tumor;   Stage II Renal Cell Cancer AJCC v7;   Stage III Kidney Wilms Tumor;   Stage III Renal Cell Cancer AJCC v7;   Stage IV Kidney Wilms Tumor;   Stage IV Renal Cell Cancer AJCC v7;   Stage V Kidney Wilms Tumor
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Childhood Malignant Neoplasm;   Cognitive Side Effects of Cancer Therapy
    Interventions:   Procedure: Cognitive Assessment;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Germ Cell Tumor;   Childhood Extracranial Germ Cell Tumor;   Childhood Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Grade 2 Immature Ovarian Teratoma;   Grade 3 Immature Ovarian Teratoma;   Malignant Germ Cell Tumor;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma;   Stage I Ovarian Teratoma;   Stage I Ovarian Yolk Sac Tumor;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma;   Stage II Ovarian Yolk Sac Tumor;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma;   Stage III Ovarian Yolk Sac Tumor;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma;   Stage IV Ovarian Yolk Sac Tumor;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
    Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cancer Survivor;   Cardiovascular Complication;   Childhood Malignant Neoplasm
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Neuroblastoma;   Stage 2A Neuroblastoma;   Stage 2B Neuroblastoma;   Stage 3 Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Superficial Bladder Cancer
    Intervention:  
    Sponsors:   University of Sydney;   Australian and New Zealand Urogenital and Prostate Cancer Trials Group;   Cancer Australia;   Cancer Council New South Wales
    Recruiting

  • Conditions:   Tailored Implementation: Online ItFits-toolkit;   Implementation as Usual
    Interventions:   Other: ItFits-toolkit;   Other: Implementation as Usual
    Sponsors:   VU University of Amsterdam;   Region of Southern Denmark;   Australian National University;   Northumbria University;   GGZ inGeest;   Badalona Serveis Assistencials;   Fondation FondaMental;   Get.On;   Azienda Sanitaria Locale 3, Torino;   Academisch Ziekenhuis Groningen;   London School of Hygiene and Tropical Medicine;   European Alliance against Depression EV;   Zyra Per Shendet Mendor;   Qendres se Shendetit the Mireqenies Komunitare;   Global alliance of mental illness advocacy networks Europe AISBL;   Black Dog Institute;   European Commission (funder)
    Recruiting

  • Conditions:   Chronic Obstructive Pulmonary Disease;   Dyspnea
    Interventions:   Drug: Placebo;   Drug: Morphine Sulfate;   Drug: Plus laxative (Docusate with senna);   Drug: Plus placebo laxative;   Device: FitBit charge HR (Accelerometer)
    Sponsor:   Flinders University
    Recruiting

  • Condition:   Clostridium Difficile Infection
    Interventions:   Biological: Clostridium difficile vaccine;   Biological: Placebo
    Sponsor:   Pfizer
    Recruiting

  • Conditions:   Mucopolysaccharidosis IV Type A;   Morquio A Syndrome;   MPS IVA
    Intervention:   Drug: Vimizim® (elosulfase alfa)
    Sponsors:   BioMarin Pharmaceutical;   ICON plc
    Recruiting

  • Condition:   Cancer Survivor
    Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer;   Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer;   Metastatic Gastric Adenocarcinoma or Cancer;   Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
    Interventions:   Drug: zolbetuximab;   Drug: placebo;   Drug: oxaliplatin;   Drug: leucovorin;   Drug: fluorouracil
    Sponsor:   Astellas Pharma Global Development, Inc.
    Recruiting

  • Condition:   Hemophilia A
    Intervention:   Biological: Valoctocogene Roxaparvovec
    Sponsor:   BioMarin Pharmaceutical
    Recruiting

  • Condition:   Hemophilia A
    Intervention:   Biological: valoctocogene roxaparvovec
    Sponsor:   BioMarin Pharmaceutical
    Recruiting

  • Condition:   Bloodstream Infections
    Interventions:   Drug: Meropenem;   Drug: Piperacillin-tazobactam combination product
    Sponsor:   The University of Queensland
    Recruiting

  • Condition:   Heart Failure
    Intervention:   Device: Cardiac Resynchronization Therapy (CRT)
    Sponsor:   Biotronik SE & Co. KG
    Recruiting

  • Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: Dapagliflozin;   Drug: Saxagliptin;   Drug: Placebo
    Sponsor:   AstraZeneca
    Recruiting

  • Conditions:   Lung Transplant;   Rehabilitation
    Intervention:   Other: Physical rehabilitation.
    Sponsor:   The Alfred
    Recruiting

  • Conditions:   Melanoma Stage Iv;   Melanoma Stage Iii;   Melanoma
    Interventions:   Drug: Denosumab;   Drug: Nivolumab;   Drug: Ipilimumab
    Sponsors:   Australia and New Zealand Melanoma Trials Group;   Peter MacCallum Cancer Centre, Australia;   Amgen;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Limited Stage Small Cell Lung Cancer;   Small Cell Lung Cancer
    Interventions:   Drug: Ipilimumab;   Drug: Nivolumab
    Sponsors:   European Thoracic Oncology Platform;   Intergroupe Francophone de Cancerologie Thoracique;   Ludwig Center for Cancer Research of Lausanne;   Frontier Science Foundation, Hellas;   Bristol-Myers Squibb
    Recruiting

  • Condition:   HER2 Positive Breast Cancer
    Interventions:   Drug: tucatinib;   Drug: capecitabine;   Drug: trastuzumab;   Drug: placebo
    Sponsor:   Seattle Genetics, Inc.
    Recruiting

  • Conditions:   High Bleeding Risk;   Coronary Artery Disease;   PCI
    Interventions:   Drug: Aspirin;   Drug: P2Y12 inhibitor
    Sponsors:   ECRI bv;   Cardialysis B.V.;   European Cardiovascular Research Center;   University of Bern;   Terumo Medical Corporation
    Recruiting

  • Condition:   Endstage Renal Disease
    Interventions:   Drug: Spironolactone 25Mg Tablet;   Drug: Placebo Oral Tablet
    Sponsors:   Population Health Research Institute;   Canadian Institutes of Health Research (CIHR)
    Recruiting

  • Condition:   Fabry Disease
    Intervention:  
    Sponsor:   Genzyme, a Sanofi Company
    Recruiting

  • Conditions:   Germ Cell Tumor;   Teratoma;   Choriocarcinoma;   Germinoma;   Mixed Germ Cell Tumor;   Yolk Sac Tumor;   Childhood Teratoma;   Malignant Germ Cell Neoplasm;   Extragonadal Seminoma;   Non-seminomatous Germ Cell Tumor;   Seminoma
    Interventions:   Drug: paclitaxel;   Drug: ifosfamide;   Drug: cisplatin;   Drug: pegylated G-CSF;   Drug: G-CSF;   Drug: carboplatin;   Drug: etoposide phosphate;   Procedure: stem cell reinfusion
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   European Organisation for Research and Treatment of Cancer - EORTC;   Movember Foundation;   Institute of Cancer Research (ICR), United Kingdom;   Cancer Research UK;   UNICANCER;   Irish Group CTI
    Recruiting

  • Conditions:   Dementia;   Dementia, Vascular;   Dementia With Lewy Bodies;   Dementia, Mixed;   Dementia Alzheimers;   Behavioural and Psychiatric Symptoms of Dementia;   Depression;   Quality of Life
    Interventions:   Other: Music Intervention;   Other: Reading Intervention
    Sponsors:   Anglia Ruskin University;   University of Melbourne;   Norwegian Academy of Music;   University of Applied Sciences Würzburg-Schweinfurt;   University School of Physical Education, Krakow, Poland;   Alzheimer's Society;   Methodist Homes for the Aged;   Saffron Hall Trust;   Cambridge and Peterborough NHS Foundation Trust
    Not yet recruiting

  • Conditions:   Acute Ischaemic Stroke;   Transient Ischaemic Attack
    Interventions:   Drug: Ticagrelor;   Drug: Placebo
    Sponsor:   AstraZeneca
    Recruiting

  • Condition:   Mucopolysaccharidosis I (MPS I)
    Intervention:  
    Sponsor:   Genzyme, a Sanofi Company
    Recruiting

  • Condition:   Mucopolysaccharidosis Type IIIB
    Intervention:  
    Sponsor:   BioMarin Pharmaceutical
    Recruiting

  • Condition:   Hypoxic-Ischemic Encephalopathy
    Interventions:   Drug: Epoetin Alfa;   Drug: Normal saline
    Sponsors:   University of Sydney;   National Health and Medical Research Council, Australia
    Recruiting

  • Conditions:   Psychotic Disorders;   Personality Disorders;   Clinical High Risk
    Interventions:   Behavioral: Support and Problem Solving Therapy;   Behavioral: Cognitive Behavioural Case Management;   Drug: Fluoxetine;   Drug: Placebo;   Behavioral: 3-monthly monitoring
    Sponsors:   Orygen Youth Health Research Centre;   National Institute of Mental Health (NIMH);   University of California, Davis;   University of California, San Francisco
    Recruiting

  • Condition:   Dystonia
    Intervention:  
    Sponsors:   Hyder A. Jinnah, MD, PhD;   National Institute of Neurological Disorders and Stroke (NINDS);   Office of Rare Diseases (ORD);   Allergan;   Dystonia Study Group
    Recruiting

  • Condition:   Hypertension
    Intervention:   Device: Ambulatory blood pressure monitoring
    Sponsors:   Italian Institute of Telemedicine;   BPLab
    Recruiting

  • Condition:   Crohn Disease
    Intervention:   Drug: Ozanimod
    Sponsor:   Celgene
    Recruiting

  • Condition:   Crohn Disease
    Interventions:   Drug: Ozanimod;   Other: Placebo
    Sponsor:   Celgene
    Recruiting

  • Condition:   Metastatic Spine Tumor
    Intervention:  
    Sponsors:   AO Clinical Investigation and Documentation;   AOSpine International
    Recruiting

  • Condition:   Crohn Disease
    Interventions:   Drug: Ozanimod;   Other: Placebo
    Sponsor:   Celgene
    Recruiting

  • Condition:   Atopic Dermatitis
    Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib
    Sponsor:   AbbVie
    Recruiting

  • Conditions:   Influenza A;   Influenza B
    Interventions:   Biological: Intravenous hyperimmune immunoglobulin (IVIG);   Biological: Placebo for IVIG
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   University of Minnesota, MN;   International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
    Recruiting

  • Condition:   Psoriatic Arthritis
    Interventions:   Drug: Adalimumab;   Drug: ABT-494;   Drug: Placebo for ABT-494;   Drug: Placebo for Adalimumab
    Sponsor:   AbbVie
    Recruiting

  • Condition:   Bladder Cancer
    Interventions:   Biological: Bacillus of Calmette-Guerin (BCG);   Drug: Mitomycin C (MMC)
    Sponsors:   University of Sydney;   Australian and New Zealand Urogenital and Prostate Cancer Trials Group;   Cancer Australia
    Recruiting

  • Conditions:   Myelodysplastic Syndrome;   MDS;   Refractory Anemia With Excess Blasts;   RAEB
    Interventions:   Drug: rigosertib;   Drug: Any approved or standard-of-care therapy;   Drug: best supportive care (BSC)
    Sponsor:   Onconova Therapeutics, Inc.
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: FT-2102;   Drug: Azacitidine;   Drug: Cytarabine
    Sponsor:   Forma Therapeutics, Inc.
    Recruiting

  • Condition:   Wet Macular Degeneration
    Interventions:   Drug: Faricimab;   Drug: Aflibercept;   Drug: Sham Procedure
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Condition:   Nonalcoholic Steatohepatitis
    Interventions:   Drug: Cenicriviroc;   Drug: Placebo
    Sponsor:   Tobira Therapeutics, Inc.
    Recruiting

  • Condition:   Early Breast Cancer
    Intervention:   Other: Endocrine therapy interruption
    Sponsors:   International Breast Cancer Study Group;   Alliance for Clinical Trials in Oncology;   Canadian Cancer Trials Group;   Breast International Group
    Recruiting

  • Condition:   ALK-positive Advanced NSCLC
    Intervention:   Drug: Brigatinib
    Sponsor:   Ariad Pharmaceuticals
    Recruiting

  • Conditions:   Myelodysplastic Syndrome;   Leukemia, Myelomonocytic, Chronic;   Leukemia, Myeloid, Acute
    Interventions:   Drug: Azacitidine;   Drug: Pevonedistat
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Condition:   Hypercholesterolemia
    Interventions:   Drug: Evinacumab;   Drug: Matching placebo;   Other: Background Lipid Modifying Therapy (LMT)
    Sponsor:   Regeneron Pharmaceuticals
    Recruiting

  • Condition:   Controlled Ovarian Stimulation
    Intervention:   Drug: Follitropin Delta
    Sponsor:   Ferring Pharmaceuticals
    Recruiting

  • Condition:   Plasma Cell Myeloma
    Interventions:   Drug: Isatuximab SAR650984;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Acetaminophen (paracetamol) or equivalent;   Drug: Ranitidine or equivalent;   Drug: Diphenhydramine or equivalent
    Sponsor:   Sanofi
    Recruiting

  • Conditions:   Neoplasm Metastasis;   Musculoskeletal Pain
    Intervention:   Drug: Tanezumab
    Sponsors:   Pfizer;   Eli Lilly and Company
    Recruiting

  • Conditions:   Influenza;   Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV);   Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
    Intervention:  
    Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   National Institute of Allergy and Infectious Diseases (NIAID);   National Institutes of Health (NIH)
    Recruiting

  • Condition:   Pompe Disease (Late-onset)
    Interventions:   Drug: AT2221;   Biological: alglucosidase alfa;   Biological: ATB200
    Sponsor:   Amicus Therapeutics
    Recruiting

  • Condition:   Pompe Disease
    Interventions:   Drug: ATB200;   Drug: AT2221
    Sponsor:   Amicus Therapeutics
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: Vincristine;   Drug: Aldesleukin;   Drug: ch14.18/CHO;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: G-CSF;   Drug: Busulfan;   Drug: Melphalan
    Sponsor:   St. Anna Kinderkrebsforschung
    Recruiting

  • Condition:   Amyloidosis
    Interventions:   Drug: Cyclophosphamide;   Drug: Bortezomib;   Drug: Dexamethasone, 40 mg;   Drug: Daratumumab
    Sponsor:   Janssen Research & Development, LLC
    Recruiting

Login to Get Started